Compare Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 (SLVO) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 vs Zimmer Biomet Holdings Inc — how do they compare? Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 trades at $69.36, while Zimmer Biomet Holdings Inc trades at $97.03 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc pays a 0.99% dividend while Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 pays none, and Zimmer Biomet Holdings Inc is trading nearer its 52-week high, Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 nearer its low. Which is the better fit depends on your goals.
| SLVO | ZBH | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $107.41 | $107.71 |
52-Week Low | $61.81 | $79.58 |
Market Cap | — | $18.55B |
Enterprise Value | — | $25.61B |
Dividend Yield | — | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLVO trades at $69.34, up 0.43% with mixed technical signals showing a bullish moving average trend but bearish oscillators including an overbought RSI. The stock recently crossed below its 50-day moving average of $73.20, indicating potential near-term pressure. Recent news highlights silver price volatility and technical breakdowns affecting this silver-focused ETN.
Outlook remains cautious with technical indicators suggesting overbought conditions while silver market volatility poses headwinds. Investment opportunity exists for traders capitalizing on silver price swings, but risks include commodity price sensitivity and technical resistance levels. The stock faces pressure from declining silver prices and dollar strength.
Zimmer Biomet (ZBH) trades at $97.9, up 0.12% on the day, with a bullish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, supported by hips, specialty businesses, and technology. Key financials show a P/E of 23.6 and net income margin of 9.48%, while cash flow from operations improved to $1.70B in 2025.
The outlook is positive, with a consensus price target of $103.56 offering ~6% upside. Risks include competitive pressures and margin volatility, but consistent earnings beats and institutional accumulation support a constructive view for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033
SLVO is an exchange-traded note issued by UBS AG that provides investors with exposure to the performance of a silver-based covered call strategy. The ETN tracks the daily return of the ISE Enhanced 100x Leveraged Silver ETN Index, which combines a long position in silver with a covered call strategy on the silver position. This strategy aims to generate current income from the option premiums, which can provide a buffer during sideways or slightly down markets for silver, but it also caps the potential gains from a significant rise in silver prices. As an ETN, it is subject to the credit risk of the issuer, UBS AG, and has an expiration date of April 21, 2033.
Read more on SLVO →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
